Drug labels updated for doxycycline, clindamycin, and caffeine citrate

Article

The National Institutes of Health has updated drug labels for doxycycline, clindamycin, and caffeine citrate. The label changes address recommended usage and dosage in pediatric populations.

Research funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health, has led to label changes regarding recommended usage and dosage in pediatric populations for doxycycline, clindamycin, and caffeine citrate.

·      The revised label for doxycycline includes weight-based dosing recommendations when treating serious diseases that have no other treatment in children aged 2 to 8 years. The label revision applies to both oral and intravenous forms of the drug.

·      Clindamycin’s revised drug label provides updates to the weight-based dosing information. The revision applies to both oral and intravenous forms of the drug.

·      Caffeine citrate, which is often used off-label in infants born before 28 weeks of pregnancy, has a revised label that states the drug may be safely given to preterm infants born earlier than 28 weeks. The dose and duration also can be higher than had been recommended in the previous drug label.

 

In a news release from the NIH, Perdita Taylor-Zapata, MD, program lead for the Best Pharmaceuticals for Children Act (BPCA) at NICHD, commented on why these label changes matter. “Doctors routinely make off-label drug decisions when treating infants and children because many drugs do not have pediatric safety or dosage recommendations. The BPCA program supports research to improve the information on labels so that health care providers have clear guidance on how to prescribe drugs for their youngest patients.”

References:

1.    National Institutes of Health (NIH). NIH-funded research leads to pediatric labeling updates for doxycycline, clindamycin and caffeine citrate [news release]. Published April 2, 2020. Accessed April 14, 2020. https://www.nih.gov/news-events/news-releases/nih-funded-research-leads-pediatric-labeling-updates-doxycycline-clindamycin-caffeine-citrate

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
© 2025 MJH Life Sciences

All rights reserved.